| 貨號 | 規(guī)格 | 價(jià)格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S80900-2mg |
99.9% | ￥240.00 | 5 | - | - | - |
|
S80900-5mg |
99.9% | ￥400.00 | 7 | - | - | - |
|
S80900-10mg |
99.9% | ￥650.00 | 6 | - | - | - |
|
S80900-25mg |
99.9% | ￥1200.00 | 6 | - | - | - |
|
S80900-50mg |
99.9% | ￥2100.00 | 5 | - | - | - |
|
S80900-100mg |
99.9% | ￥3800.00 | 5 | - | - | - |
|
CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively.
| 產(chǎn)品描述： | CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | Aurora A:8 nM (Ki);Aurora B:9.2 nM (Ki) | ||||||||||||||||||||
| 體內(nèi)研究： | Oral administration of CYC-116 at dose levels of 75 and 100 mg/kg q.d. causes tumor growth delays of 2.3 and 5.8 days, which translates into specific growth delays of 0.32 and 0.81, respectively. The mean relative tumor volumes of mice receiving CYC-116 at both dose levels are less than those of vehicle-treated mice for the duration of the study period. At 100 mg/kg po q.d., the reduction in growth is statistically significant on days 6 and 9 | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1. Wang S, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78. | ||||||||||||||||||||
| 溶解性： | DMSO : 15 mg/mL (40.71 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險(xiǎn)品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京